SEOUL, South Korean biopharmaceutical firm Celltrion Inc. said Monday its new autoimmune disease treatment, Zymfentra, has made a debut in the U.S. market. Zymfentra, a subcutaneous injection formulation of Celltrion's infliximab Remsima, won approval from the U.S. Food and Drug Administration last year for use on patients who suffer ulcerative colitis or Crohn's disease. Celltrion said it has set an optimal price for the drug considering the prices of its competing products, and aims to reach more than 10 percent of its target patients with Zymfentra by 2025 to raise 1 trillion won (US$750.3 million) in annual sales. Zymfentra's main target is the U.S. inflammatory bowel disease treatment market with a size of 12.8 trillion won, the Korean company said, citing data from health care researcher IQVIA. The company added the treatment will play a pivotal role in Celltrion Group's long-term strategy to reach an annual sales target of 12 trillion won by 2030. Source: Yonhap News Agency